Previous close | 10.70 |
Open | 9.35 |
Bid | 9.80 |
Ask | 10.30 |
Strike | 160.00 |
Expiry date | 2025-03-21 |
Day's range | 9.35 - 10.12 |
Contract range | N/A |
Volume | |
Open interest | 696 |
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo Nordisk announced results from the phase 3 FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment (regular treatment to prevent prolonged and spontaneous bleeding) w
Edward Sheldon's been contributing to his SIPP to build wealth for retirement. Here’s a look at where he’s investing his money. The post I just put £4k into my SIPP. Here’s where I’m going to invest it appeared first on The Motley Fool UK.
In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.